Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 35/100

Failure Rate

17.2%

15 terminated/withdrawn out of 87 trials

Success Rate

77.9%

-8.6% vs industry average

Late-Stage Pipeline

62%

54 trials in Phase 3/4

Results Transparency

85%

45 of 53 completed trials have results

Key Signals

11 recruiting45 with results13 terminated

Enrollment Performance

Analytics

Phase 3

39(60.0%)

Phase 4

15(23.1%)

Phase 2

7(10.8%)

N/A

2(3.1%)

Phase 1

2(3.1%)

65Total

Phase 3(39)

Phase 4(15)

Phase 2(7)

N/A(2)

+1 more

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (87)

Showing 20 of 87 trials

NCT02972281Not ApplicableCompleted

Systematic Search for Primary Immunodeficiency in Adults With Infections

Role: collaborator

NCT04376762Phase 4Completed

Comparison of Fibrinogen Concentrate and Cryoprecipitate in Pediatric Cardiac Surgery Patients

Role: collaborator

NCT04953884Phase 3Completed

Efficacy, PK, Immunogenicity and Safety of Wilate in Severe Von Willebrand Disease (VWD) Patients <6 Years of Age

Role: lead

NCT06096116Phase 3Recruiting

Phase 3 Study on the Efficacy and Safety of Human Plasma Derived Antithrombin (Atenativ) in Heparin-Resistant Patients Scheduled to Undergo Cardiac Surgery Necessitating Cardiopulmonary Bypass

Role: lead

NCT05936580Phase 4Recruiting

Nuwiq Dosing and Outcomes In the ManagEment of Women/Girls With Haemophilia A Needing FVIII Treatment for Surgery

Role: lead

NCT04508530Phase 3Completed

Phase III Study To Compare The Effect of Panzyga Versus Placebo in Patients With Pediatric Acute-onset Neuropsychiatric Syndrome (PANS/PANDAS)

Role: lead

NCT04146376Recruiting

Von Willebrand Factor in Pregnancy (VIP) Study

Role: collaborator

NCT04918173Phase 3Recruiting

Efficacy of Atenativ in Patients With Congenital Antithrombin Deficiency Undergoing Surgery or Delivery

Role: lead

NCT04867837Phase 3Recruiting

Study of OCTAPLEX in Patients With Acute Major Bleeding on DOAC Therapy With Factor Xa Inhibitor

Role: lead

NCT03695978Recruiting

Efficacy, Safety & Utilisation of Nuwiq, Octanate and Wilate in Previously Untreated & Minimally Treated Haemophilia A Patients

Role: lead

NCT07220915Phase 3Not Yet Recruiting

Supporting Weak Immune System During Autoimmune Therapy: Testing Panzyga to Prevent Infections

Role: lead

NCT05935358Phase 4Recruiting

Nuwiq for Perioperative Management Of Patients With Haemophilia A on Emicizumab Regular Prophylaxis Study

Role: lead

NCT06361537Phase 3Recruiting

Study of IV Human Plasma-derived C1 Esterase Inhibitor Concentrate in Patients With Congenital C1-INH Deficiency for Treatment and Pre-procedure Preventing of Acute Hereditary Angioedema Attacks

Role: lead

NCT04640142Phase 3Active Not Recruiting

Study to Evaluate the Pharmacokinetics, Efficacy, Tolerability, and Safety of Subcutaneous Human Immunoglobulin (Newnorm) in Patients With Primary Immunodeficiency Diseases

Role: lead

NCT04502030Phase 3Completed

Double-blind, Randomized, Placebo-controlled, Prospective Phase III Study Evaluating Efficacy and Safety of Panzyga in Primary Infection Prophylaxis in Patients With Chronic Lymphocytic Leukemia ("PRO-SID" Study)

Role: lead

NCT04023019Recruiting

Treatment of Hemophilia A Patients With FVIII Inhibitors

Role: collaborator

NCT05523297Phase 3Completed

Active-control Randomized Trial Comparing 4-factor Prothrombin Complex Concentrate With Frozen Plasma in Cardiac Surgery

Role: lead

NCT03793426Terminated

Safety and Efficacy of Fibryga in Congenital Fibrinogen Deficiency

Role: lead

NCT04929236Phase 3Recruiting

Study to Evaluate Safety and Efficacy of Different PANZYGA Dose Regimens in Pediatric Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) Patients

Role: lead

NCT06429787Recruiting

Post Marketing Observational Study on Safety of BALFAXAR vs. KCENTRA for Reversal of Vitamin K Antagonist Induced Anticoagulation in Adults Undergoing Urgent Surgery or Invasive Procedure

Role: lead